Epigenetic inhibitors for the precision treatment of ARID1A-mutant ovarian cancers: what are the next steps?

Expert Rev Precis Med Drug Dev. 2018;3(4):233-236. doi: 10.1080/23808993.2018.1503050. Epub 2018 Jul 25.

Authors

Takeshi Fukumoto¹, Rugang Zhang¹, Benjamin G Bitler²

Affiliations

¹ Gene Expression and Regulation Program, The Wistar Institute, Philadelphia, PA 19104.
² Department of Obstetrics & Gynecology, University of Colorado Anschutz Medical Campus, Research Complex-2; MS8613, 12700 East 19th Avenue, Aurora, Colorado 80045.

No abstract available

Keywords: ARID1A; EZH2; Epigenetics; HDAC; SWI/SNF; ovarian cancer.

Grants and funding